SAN DIEGO, May 12, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that the Company will highlight clinical development plans for its Phase 3-ready pegylated arginine deiminase, ADI-PEG 20, during a symposium held on Tuesday, May 24, at 1:30 p.m. China Standard Time in Taipei, Taiwan.
Details about Polaris' upcoming pivotal Phase 3 clinical trial of ADI-PEG 20 in hepatocellular carcinoma (HCC) will be presented by the principal investigator, Ghassan Abou-Alfa, M.D., of Memorial Sloan-Kettering Cancer Center in New York. This presentation will include plans for enrollment in the global trial with sites in the United States, Taiwan, China and parts of Europe. Additional presentations during the symposium will provide updates for ongoing Phase 2 studies in small cell lung cancer and mesothelioma, as well as an outline of future development plans for ADI-PEG 20.
"This symposium comes at an important time for Polaris as we prepare for a global Phase 3 trial of ADI-PEG 20 treating hepatocellular carcinoma patients for which our Special Protocol Assessment was recently approved by the FDA," said Bor-Wen Wu, Ph.D., president and chief executive officer of Polaris Group. "We are proud to have multiple distinguished physicians present at this event and discuss the next steps in advancing ADI-PEG 20 through clinical development."
Presentations will focus on various aspects of the plan to investigate the potential for ADI-PEG 20 in indications beyond HCC. Wu will present a broad overview of future clinical development plans for the therapeutic candidate, while individual physicians will discuss specific studies.
Background about the ongoing Phase 2 clinical trials of ADI-PEG 20 in small cell lung cancer and mesothelioma will be presented by the lead investigator of the mesothelioma study, Peter Szlosarek, M.D., Ph.D., of the Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London. <
|SOURCE Polaris Group|
Copyright©2010 PR Newswire.
All rights reserved